CoChat

Efficacy of biologics in atopic dermatitis

Wu, Jianni, Guttman-Yassky, Emma · 2020 · Expert Opinion on Biological Therapy

The DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.

Abstract

Introduction: Atopic dermatitis (AD) is a heterogeneous disease. Recent advancements in understanding AD pathogenesis resulted in the exponential expansion of its therapeutic pipeline, particularly following the success and FDA-approval of dupilumab. Different phenotypes of AD by age and ethnicity have also recently been described and clinical studies of emerging treatments will further clarify the role of each cytokine pathway in AD.Areas covered: We review the impressive repertoire of biologics for treatment of moderate-to-severe AD, including those targeting Th2, Th22, Th17/IL-23 and IgE. We highlight the scientific rationale behind each approach and provide a discussion of the most recent clinical efficacy and safety data.Expert opinion: AD is a complex disease and recent research has identified numerous endotypes, reinforcing the rationale for developing targeted therapeutics to antagonize these factors. Dupilumab has revolutionized AD treatment and its mechanistic studies also offer crucial insight into AD pathogenesis. Nevertheless, this biologic does not work for everyone, highlighting the need for a more precise approach to address the unique immune fingerprints of each AD subset. Ultimately targeted therapeutics will complement our understanding of the AD molecular map and help push AD management into an era of personalized medicine.

Overview

Integrity signals

Registry

Crossref · 10.1080/14712598.2020.1722998

Cites

172 of 172 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 172 references

Research works printed but not linked: 6

  1. TC SR C, 2018, J Invest Dermatol, 138(5, Suppleme
  2. He H, 2020, Ann Allergy Asthma Immunol, 124
  3. Gooderham MJ, 2020, JAMA dermatology, 155
  4. Eyerich S, 2009, J Clin Invest, 119, 3573
  5. Weber A, 2010, Sci Signal, 3, cm1
  6. 10.1038/nri2691 · DOI · Paper page

Cited by

See all 46

Metadata

Authors
Wu, J., & Guttman-Yassky, E.
Affiliations
  • SUNY Downstate Health Sciences University (US)
  • Department of Dermatology, Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, USA
Venue
Expert Opinion on Biological Therapy
Published
2020-02-03
Volume
20
Issue
5
Pages
525-538
ISSN
  • 1471-2598 (ISSN-L)
  • 1744-7682
OpenAlex
W3004019018
Cited by
46
References
172
Citations by year
2026: 3 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 7 · 2021: 17 · 2020: 9
FWCI
1.46
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Biological Therapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
Keywords
atopic dermatitis, biologic therapy, dupilumab, Th2 cytokines, IgE, disease endotypes, personalized medicine, moderate-to-severe atopic dermatitis, treatment efficacy and safety
MeSH terms
Interleukin-22, Antibodies, Monoclonal, Biological Products, Dermatitis, Atopic, Humans, Immunoglobulin E, Interleukins, Th2 Cells, Interleukin-17, Interleukin-23, Th17 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of biologics in atopic dermatitis. https://app.cochat.ai/papers/10.1080/14712598.2020.1722998
The paper
Wu, J., & Guttman-Yassky, E. (2020). Efficacy of biologics in atopic dermatitis. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2020.1722998

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.